okazaki

Who is “Ron Fischer/Richard Graydon”? How did he invent a CV and resume good enough to secure jobs at two biotech companies? What was “Graydon” like as a coworker? Did “Graydon” work with other companies in the 20 yrs he was on the run? I am seeking answers to all these questions and more. If you know something, my DMs are open and my Signal user ID is stataf.54 Reach out, please.

This is a MASSIVE failure guys @Apple This is how I search the web. This needs to be fixed @MKBHD please call Tim Apple

@MartinShkreli Honestly forget average, I’d put more weight in a junior associate to give me this feedback. And usually for free!

@MartinShkreli Decks: I see >1000/y Term sheets: I see > a dozen/y Assets: I see 100s, deep dive on 10-20/y BD: I talk to heads of BD every mo Lit: I lose (who cares) Board: 4 board meetings per portco/y Counting up paper like I'm counting my sets, put the work in daily, had to earn my reps

Unfortunately the average VC has an order of magnitude more knowledge across these domains than even a successful operator.

@PositiveTopline We are all above average

@oakazaki The average VC:

@Mykalt45 Founders should improve their POS. I think operators can provide a lot more value on team building leadership etc.

@oakazaki Why can’t founders learn more and improve their POS? And VCs aren’t the only path to creating value.

@masterlongevity Well every VC is top quartile, so…

@oakazaki Maybe the top tier of biotech vcs, but certainly not the average ones

to hear Trump tell it, American elections were completely corrupted while he was president and he was helpless to stop it, then they were cleaned up by Biden ahead of Trump's victory in 2024, and now that Trump is president again they are once again becoming third world-caliber

@bijans Initial markets seem to be avoiding the pot’l ethical issues others have raised.

Looks like Kalshi biotech is live

@DavidSacks What is the use case for generative AI? And does that use case justify the investment being made? If the Chinese can make slop generators cheaper than we can, we should let them

Our billionaires used to have a deep sense of civic responsibility, and through great acts of service and philanthropy established public goods to be enjoyed by all. Rockefeller bought 11k acres for Acadia National Park and built the carriage trail system. Carnegie helped build over 1,500 libraries in America. But sure…invest the money in Super PACs and NGOs to “beat back Marxism”. GMAFB. Sorry. They did this to themselves. Not a statement on policy, just that they FAFO. “There's a storm coming, Mr. Wayne. You and your friends better batten down the hatches, because when it hits, you're all gonna wonder how you ever thought you could live so large and leave so little for the rest of us.”

@drug_smolecules @a_a_free That’s LPA

@a_a_free that's... not... 😮‍💨

Perfect call on $GSK

@Dremontjones @srikosuri Compromises trial blinding

@srikosuri but free markets yield better information than surveys

Trials are ultimately experiments on people. I really don’t like this from an ethical lens, and it opens up a can of worms. Would people enroll in non-consensus trials? should patients know the betting odds of trials they are enrolling in; would it lead to better decision making for patients? Can companies hedge their own risk in a trial; would that lead to incentive for bad behavior? Would this allow for capitalizing more trials? I certainly don’t know the answers to these questions, but it worries me and the consequences of it going badly are big (if it actually catches on).

@Archimedes20311 Definitely won’t be any insider trading.

womp womp

@AlmostMedia 99% return rate here

Shopping Quince is very challenging as they seem to have made lack of merchandising consistency their core value proposition. Do people just have very high return rates with trial and error?

How do you think it would have been covered if President Obama had to pay $5 million to a woman he sexually abused and defamed? Do you think the White House press would have asked him about it?

@endowment_eddie No fees on coinvest ;)

In private equity broadly, the tail is wagging the dog. Big LPs are increasingly pushing GPs to manufacture coinvest or manufacture special vehicles.

@epickram @drsprs Myosin inhibitors are going to inhibit myosin. It’s on brand. Braveheart baseline LVEF is significantly lower than mava and afi. And still 10% of their patients hit LVEF <50% in the high dose. With two titration steps.

@oakazaki @drsprs Initial dose work well for most patients so it’s quicker than afi. More rapid onset of efficacy allows u to extract greater remodeling effects in an nHCM trial and their echo/structural data do support that concept

It's a me-three drug from China. With exact same MOA of 2 FDA approved drugs. Why does this "thing" exist? Go fund new targets FFS. Yeah really "brave" to develop this. $BRVE "BHB-1893, is an oral small-molecule cardiac myosin inhibitor licensed from Jiangsu Hengrui Pharmaceuticals in September 2025, being developed for both obstructive (oHCM) and non-obstructive (nHCM) forms of HCM."

@dshahh @AppleHelix $1800M pre doesn’t feel very efficient

@oakazaki @AppleHelix U don’t. but there’s a narrative you could draw by pointing at BBIO or ROIV and saying we can do it better/more efficiently w AI native. Whether it works…🤷🏽‍♂️

I really don’t understand how the venture math on a $200m raise at $2B post will work. Do you play the liquidation preference game? 3x participating preferred? Full ratchet? Warrants? These are Tech valuations without the possibility of Tech venture returns